Looking Beyond the Light at the End of the Tunnel

Considerations for post-pandemic management of cardiometabolic clinical trials


Michael Murphy, MD, PhD | Eteri Tsetskhladze, MD, PhD, FESC, FACC | Jeffrey Zucker, MS

Cardiometabolic clinical research was affected by healthcare directives curtailing outpatient and elective procedures, as well as those encouraging people to stay home whenever possible. In response to these protocols, new guidances emerged from FDA, EMA, and ESC to enable clinical trials to adapt under COVID-19 conditions. The experts at Worldwide Clinical Trials outline operational shifts made in response to the pandemic and predict how they impact the future of cardiovascular studies.

Your form has been successfully submitted! Click the button below to access.
VIEW PDF
Michael Murphy, MD, PhD
MEET THE AUTHOR

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
LEARN MORE
Eteri Tsetskhladze, MD, PhD, FESC, FACC
MEET THE AUTHOR

Eteri Tsetskhladze, MD, PhD, FESC, FACC

Vice President, General Medicine Medical Lead, Medical Affairs
LEARN MORE
Jeffrey Zucker, MS
MEET THE AUTHOR

Jeffrey Zucker, MS

Senior Vice President, Global Clinical Operations, Site Management & Trial Optimization
LEARN MORE